Apellis Pharmaceuticals, Inc. (APLS) Q1 2021 Earnings Results

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.33%

The earnings report indicates that Apellis Pharmaceuticals is facing challenges, particularly reflected in their EPS miss. The stock reacted slightly down by 0.33%, suggesting that investors may be cautious about the company's financial health. The lack of revenue figures and guidance adds to the uncertainty surrounding future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-2.32	N/A	-39.26%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over the current financial performance. They did not provide detailed insights into future strategies or expectations.

Management did not provide specific revenue figures or future guidance.

The company acknowledged challenges in meeting earnings expectations.

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.33%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.33%

Key numbers

Management commentary